The Shotlee Journal
Browse Shotlee articles about GLP-1 Medications.
Showing 9 / 934 GLP-1 Medications articles
ShantaQuilette Carter-Williams shares her experience with GLP-1 medication after a health ultimatum. Discover how it transformed her life, health habits, and perspective on self-care.
The ongoing discussion regarding insurer coverage for GLP-1 medications such as Ozempic and Wegovy has reignited a familiar debate concerning the origins of illness. Some argue these weight-loss drugs are shortcuts, while others emphasize the impact of socioeconomic factors on body weight.
A recent study has uncovered a potential connection between glucagon-like peptide-1 (GLP-1) receptor agonists and chronic cough in individuals managing type 2 diabetes. The research suggests that those using GLP-1 drugs were more prone to developing a persistent cough compared to those on alternative second-line treatments.
GLP-1 drugs are prescription medicines utilized to treat type 2 diabetes and aid weight loss under medical supervision. These medications work by imitating hormones responsible for controlling blood sugar and appetite. It is important to obtain them from regulated sources.
Drug manufacturers are creating oral GLP-1 medications for obesity management. Injectable GLP-1 drugs like Ozempic have limitations, but pill versions offer a new option. One Wegovy pill is anticipated to receive FDA approval this year.
ShantaQuilette Carter-Williams shares her experience with GLP-1 medications after facing serious health issues. Her story highlights the transformative impact on her health, lifestyle, and relationships.
Eli Lilly has submitted orforglipron, its oral GLP-1 therapy, for FDA approval following successful phase 3 trial outcomes. The weight loss pill demonstrates promise in addressing weight regain issues often seen when patients discontinue GLP-1 therapy. The study showed patients maintained weight loss for up to a year.
WeightWatchers is undergoing a brand refresh to better integrate GLP-1 medications into its offerings. This shift comes after the company's bankruptcy filing, which cited the rapidly evolving weight management landscape. The rebrand includes new programs and features designed to support members using these medications.
Eli Lilly is currently thriving, fueled by the success of its GLP-1 drugs. However, factors such as market competition and the eventual expiration of patent protections pose potential challenges to its long-term growth.
